Picture of Knight Therapeutics logo

GUD Knight Therapeutics Income Statement

0.000.00%
ca flag iconLast trade - 00:00
HealthcareConservativeSmall CapHigh Flyer

Annual income statement for Knight Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.

C2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue12.547.5200243294
Cost of Revenue
Gross Profit10.326.981.7115138
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses18.364.5232256332
Operating Profit-5.78-17.1-32.1-12.4-38.8
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes29.522.832.16.69-44
Provision for Income Taxes
Net Income After Taxes24.11831.815.7-29.9
Minority Interest
Net Income Before Extraordinary Items
Net Income24.114.542.115.7-29.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income24.114.542.115.7-29.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS0.1660.1970.4030.135-0.135